Artificial intelligence is accelerating discovery across the life sciences. From drug development to materials science, AI is helping researchers move faster and solve problems once thought intractable. This convergence of AI and biology holds extraordinary promise for human health, economic growth, and scientific leadership.
At the same time, advances in AI technologies are introducing new risks, like re-engineered toxins and pathogens. As these tools become more capable and widely accessible, they can lower barriers not only to scientific discovery, but also to accidental harm and deliberate misuse. For example, recent research has shown that specialized AI tools for protein design can be used to re-engineer toxins in ways that may preserve harmful function while evading some existing synthesis safeguards. That work revealed vulnerabilities in screening systems designed for an earlier technological era—and also showed that those systems can be strengthened through coordinated action across industry, government, and the scientific community.
Rising biosecurity concerns are not a reason to slow innovation, but they are a reason to strengthen our defenses. History shows that powerful general-purpose technologies become more accessible—as with advances in networking and computing—effective governance depends on developing technical and policy safeguards early, before misuse outpaces controls and oversight. The convergence of AI and biology presents a similar challenge: we must preserve the openness that fuels discovery while modernizing protections for a new era of capability.
This blog examines how advances across the AI-biology ecosystem are reshaping both opportunity and risk. It explains why nucleic acid synthesis screening has emerged as a critical control point, and how government, industry, and the scientific community can work together to strengthen biosecurity without slowing innovation.
AI and biotechnology at the frontier
To better understand the trajectory of AI capabilities in the biosciences—and the associated policy and risk landscape—it is useful to distinguish among four related types of advances. Each matter on its own, but effective policy will need to account for how these advances increasingly interact and reinforce one another.
- Generalist models. Advances in general-purpose AI models, such as ChatGPT, Gemini, Claude, and others, are expanding the range and sophistication of what these systems can understand, reason through, plan, and generate across domains. As they become more powerful, they raise baseline capabilities and lower barriers to sophisticated technical work.
- Specialized biological design tools. Computer scientists and biologists continue to develop specialist AI code bases aimed at performing computation in support of increasingly sophisticated biological tasks. These tools, typically open-sourced and shared widely, include programs that compute protein structure from amino –acid sequences and design proteins with specific structures and properties .
- Laboratory automation. Advances in computer vision, robotics, and experimental workflows are bringing new efficiencies to laboratory work. Over time, these systems may allow researchers to generate, test, and refine biological designs at greater scale and speed.
- Agentic systems. Agentic programming environments and run–times (including increasingly powerful AI-based engineering tools, e.g., Claude code) are making it easier to combine generalist AI models, specialist libraries, and laboratory workflows into coordinated pipelines. This may allow less experienced actors to move more readily from computational design to real-world synthesis, including through nucleic acid synthesis services or automated laboratory systems.
While each category can be analyzed separately, the most consequential developments arise from how these capabilities increasingly interact. Improvements in generalist models can make specialized biological tools easier to use; those tools make it easier to engineer biology; automated laboratories provide non-experts with access to sophisticated laboratory workflows; and agentic programming tools can connect these elements into integrated design, analysis, and synthesis workflows. Together, these advances are forming a converging “capability stack”—one that can accelerate innovation but lead to a more complex policy and risk landscape.
Why nucleic acid synthesis screening matters
These developments make clear that effective governance must focus not only on frontier models but also expand to consider multiple practical control points.
One of the most effective near‑term defenses against biological misuse is nucleic acid synthesis screening. Synthetic DNA providers sit at a critical checkpoint in the biotechnology ecosystem. They are often the place where theoretical biological designs are translated into physical reality. Screening DNA orders and verifying customers helps ensure that powerful tools are used for legitimate purposes and not diverted toward harm.
Today, however, most DNA synthesis screening remains voluntary and unevenly applied. Standards vary across providers, and there is no universal requirement that all orders be screened to the same level. As AI‑enabled design tools grow more powerful, these gaps become more consequential.
Strengthening nucleic acid synthesis screening is a pragmatic and targeted response. It does not regulate ideas or restrict legitimate research. Instead, it focuses on responsible access to sensitive capabilities, reinforcing a line of defense that already exists but must now be modernized. The necessity and viability of such modernization was demonstrated by the Paraphrase Project, led by Microsoft. By stress-testing existing screening systems against AI-designed biological sequences, the project showed both where safeguards could fail and how they could be improved. The effort followed a familiar model from cybersecurity: responsible disclosure, red teaming, and rapid deployment of fixes. It highlights how biosecurity tools, like software, must evolve continuously to keep pace with changing threats.
Bipartisan momentum and durable government action
The importance of biosecurity in the age of AI has been recognized across administrations and parties. On May 5, 2025, the Trump Administration released an Executive Order on Improving the Safety and Security of Biological Research, emphasizing the importance of nucleic acid synthesis screening and calling for broader biosecurity oversight. That action built on work that began in 2024, when the White House Office of Science and Technology Policy set out a federal framework emphasizing comprehensive screening, customer verification, and the development of technical standards in partnership with industry.
Leaders in Congress are now building on this foundation. Earlier this year, Senators Cotton and Klobuchar introduced the Biosecurity Modernization and Innovation Act, known as S. 3741. The bill reflects a bipartisan commitment to strengthening U.S. biosecurity while sustaining scientific leadership and innovation. It would establish mandatory screening requirements (extending beyond current requirements for screening for federally funded research), conformity assessments, and enforcement mechanisms, while also advancing practical implementation through technical assistance and a biotechnology governance sandbox to promote exploratory efforts. The bill also directs OSTP to conduct a 90-day assessment of biosecurity authorities and develop a plan to consolidate oversight to improve efficiency and effectiveness.
Taken together, these efforts reflect a durable consensus: safeguarding biotechnology in the AI era is a national security priority.
Responsible innovation in practice
Supporting innovation while reducing risk will require a balanced approach grounded in continuous monitoring of emerging capabilities, investment in technical safeguards, and thoughtful policy development.
Nucleic acid synthesis screening is not a comprehensive solution, but it is an essential one. Strengthening it now—through bipartisan legislation, thoughtful regulation, and continued public‑private collaboration—would represent the type of balanced, durable action that this moment requires.
The Biosecurity Modernization and Innovation Act would help advance that goal by pairing stronger screening requirements with practical implementation tools and oversight mechanisms. Microsoft strongly supports efforts like this that build on our longstanding work with researchers, synthesis providers, and other partners to strengthen safeguards while sustaining innovation.
The United States has an opportunity to continue to lead by pairing innovation with responsible stewardship. If we get this balance right, we can reap the rewards of AI-enabled biotechnology while guarding against its risks—for this generation and the next.
Additional resources: